코아스템켐온
Financials
Valuation Metrics
코아스템켐온's Market Cap is ₩865B. At end of 2025 it was ₩977B. Ranked #1316 of 2,405 in KR market (top 55%), #724 of 1,627 on KOSDAQ (top 44%), #147 of 231 in Pharmaceuticals, Biotechnology & Life Sciences (top 64%) by Market Cap.
Investment Metrics(as of 2026-11-02)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | 86.50B KRW | KR#1,316/2,405 Sec#147/231 |
| Revenue | 18.29B KRW | KR#2,158/2,405 Sec#160/231 |
| Net Income | -27.81B KRW | KR—/2,405 Sec—/231 |
| Total Assets | 104.01B KRW | KR#1,741/2,405 Sec#138/231 |
| Net Assets | 44.40B KRW | KR#1,980/2,405 Sec#171/231 |
| Employees | 376 | KR#646/2,405 Sec#56/231 |
| Value | ||
| P/B | 1.95x | KR#1,964/2,405 Sec#145/231 |
| P/S | 4.73x | KR#2,143/2,405 Sec#145/231 |
| FCF Yield | -18.41% | KR—/2,405 Sec—/231 |
| Profitability | ||
| ROE | -62.63% | KR#2,287/2,405 Sec#204/231 |
| ROA | -26.74% | KR#2,279/2,405 Sec#193/231 |
| Op. Margin | -113.93% | KR#2,297/2,405 Sec#178/231 |
| Revenue Growth | -26.34% | KR#2,179/2,405 Sec#195/231 |
| Financial Health | ||
| Debt Ratio | 134.26% | KR#1,816/2,405 Sec#202/231 |
| Total Debt | 36.71B KRW | KR#1,131/2,405 Sec#80/231 |
| FCF | -15.92B KRW | KR#1,826/2,405 Sec#172/231 |
| Cash | 4.44B KRW | KR#2,044/2,405 Sec#192/231 |
| Current Ratio | 0.27x | KR#2,200/2,405 Sec#216/231 |
| Performance | ||
| 1Y Return | 5.55% | KR#382/2,405 Sec#23/231 |
| 1M Return | -29.33% | KR#2,214/2,405 Sec#219/231 |
| From 52W High | -73.18% | KR#2,154/2,405 Sec#191/231 |
| 1Y MDD | -65.92% | KR#1,764/2,405 Sec#151/231 |
| Trading | ||
| Volume | 59,852 shares | KR#860/2,405 Sec#95/231 |
| Trading Value | 98.4M KRW | KR#1,447/2,405 Sec#155/231 |
| Foreign Own. | 1.22% | KR#1,929/2,405 Sec#189/231 |
| Per Share | ||
| EPS | -526 KRW | KR—/2,405 Sec—/231 |
| BPS | 840 KRW | KR#2,326/2,405 Sec#218/231 |
Company Info
Established in 2003 and listed on KOSDAQ in 2015, Corestem ChemOn merged with Kellun Co., Ltd., a top-three domestic non-clinical Contract Research Organization, in 2022. The company specializes in the production and sale of treatments for rare and intractable diseases based on stem cell technology, successfully commercializing stem cell therapies since 2015. It collaborates with clinical centers to develop and rapidly commercialize cell therapies, aiming to become a global leader through overseas license-out agreements and expanded indications. Corestem ChemOn is headquartered in Seongnam-si, Gyeonggi-do.